EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphoma (biopharminternational.com)

Because your title mentions EC, I just learned it’s the EC that approves the market authorisation. I always thought it was the EMA but apparently this is “just” a recommendation and in some cases the EC and EMA disagree.